The focus of this good practice paper (GPP) is to provide practical guidance on patient assessment, treatment administration and toxicity management relating to treatment with anti-CD3 × CD20 bispecific antibodies (BsAb) as currently approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and/or European Medicines Agency (EMA). The role of these antibodies in the treatment pathway of large B-cell lymphoma (LBCL) or follicular lymphoma (FL) is beyond the scope of this paper, but the former is covered in the BSH Guideline for the management of relapsed or refractory (R/R) LBCL.
Declaration of Interests
The BSH paid the expenses incurred during the writing of this good practice paper. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.